No Data
No Data
Consun Pharma (01681.HK): SK-08 tablet clinical trial approval notice, iodine cresol injection pharmaceutical registration approval.
On July 18th, Consun Pharma (01681.HK) announced that the company has received the "Drug Clinical Trial Approval Notice" approved by the National Medical Products Administration ("NMPA") for the clinical trial application of SK-08 tablets ("SK-08 Tablets"). It is intended for the treatment of chronic kidney disease ("CKD"). SK-08 tablet is a new type of chemical drug jointly developed by the group and Shanghai Wuxi AppTec Co., Ltd. After obtaining the above approval from the NMPA, clinical trials will be initiated soon. On July 9th, 2024, the group indirectly holds all the shares.
Express News | Consun Pharmaceutical - Approvals Issued by Nmpa of China
Express News | Consun Pharmaceutical - Drug Registration Approval for Iodixanol Injection
Express News | Consun Pharmaceutical - Notice of Approval for Clinical Trial of Drug for SK-08 Tablet
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Consun Pharma (1681.HK): The management's significant increase in shareholding boosts market confidence.
In the first half of 2024, under the market capital preference for value stocks, Consun Pharma, with its stable growth performance and continuous high-proportion dividend strategy over the years, has been bullish by many investors and analysts. The pre-right price cumulative increase is over 33%, and the price volatility is over 51%. The highest price is HKD 7.16, which obviously outperforms the Hang Seng Index and the Hong Kong stock pharmaceutical sector. Since mid-May, affected by the adjustment of the Hong Kong stock market and the exercise of subscription rights by the company's first and second largest shareholders, investors have misunderstood this operation as high-level reduction of shareholding by shareholders, leading to a slight retreat of Consun Pharma's stock price. Recently, Consun
No Data